Lisata Therapeutics
LSTA
24 hedge funds and large institutions have $2.44M invested in Lisata Therapeutics in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
494% more call options, than puts
Call options by funds: $291K | Put options by funds: $49K
60% more capital invested
Capital invested by funds: $1.52M → $2.44M (+$917K)
0.06% more ownership
Funds ownership: 0.53% → 0.59% (+0.06%)
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$847K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$140K |
| 3 |
Jane Street
New York
|
+$21.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$8.94K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.97K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$3K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$1.76K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1K |
LSTA Hedge Fund Activity: Q2 2020 in Review
24 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q2 2020, worth a combined $2.44M — up 60% from $1.52M a quarter earlier.
Fund positioning in LSTA was balanced in Q2 2020: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $847K. The largest seller was UBS Group, cutting an estimated $8.94K.
- 24 institutional investors held Lisata Therapeutics (LSTA) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $2.44M of Lisata Therapeutics stock for Q2 2020, up 60% quarter-over-quarter.
- 3 funds opened new Lisata Therapeutics positions in Q2 2020 and 3 closed out, a net change of 0 holders.
- The largest Lisata Therapeutics buyer in Q2 2020 was Renaissance Technologies, an estimated $847K added.
- The largest Lisata Therapeutics seller in Q2 2020 was UBS Group, an estimated $8.94K sold.
Based on aggregated 13F filings for Q2 2020.